KIR2DL1/CD158a Antibody (MM0438-11G25) [Janelia Fluor® 549] Summary
Immunogen |
Human recombinant KIR2DL1/CD158a |
Specificity |
This antibody detects KIR2DL2, KIR2DL3, KIR2DS2, and KIR2DS4. |
Isotype |
IgG2 |
Clonality |
Monoclonal |
Host |
Mouse |
Gene |
KIR2DL1 |
Purity |
Protein G purified |
Innovator's Reward |
Test in a species/application not listed above to receive a full credit towards a future purchase. |
Applications/Dilutions
Dilutions |
|
Application Notes |
Optimal dilution of this antibody should be experimentally determined. |
Packaging, Storage & Formulations
Storage |
Store at 4C in the dark. |
Buffer |
50mM Sodium Borate |
Preservative |
0.05% Sodium Azide |
Purity |
Protein G purified |
Notes
Sold under license from the Howard Hughes Medical Institute, Janelia Research Campus.
Alternate Names for KIR2DL1/CD158a Antibody (MM0438-11G25) [Janelia Fluor® 549]
Background
KIRDL2, also known as CD158a, belongs to the killer-cell immunoglobulin-like receptor (KIR) gene family expressed by natural killer (NK) cells and functions in inhibitory signaling (1,2). The KIR genes consisting of 15 gene loci and two pseudogenes are located on chromosome 19 and segregated into halptype A or B depending on gene composition (1). Human KIR2DL1 belongs to haplotype A and is synthesized as a protein of 348 amino acids (aa) in length with a theoretical molecular weight (MW) of 38.5 kDa (3). The KIR2DL1 protein consists of two extracellular immunoglobulin (Ig)-like C2 domains, a transmembrane domain, and a long cytoplasmic tail containing an immunoreceptor tyrosine-based inhibitory motif (ITIM) (1,3). KIR2DL1 binds human leukocyte antigen (HLA) alleles with the C2 supratype, resulting in an inhibitory immune response and suppression of NK cell activity to target cells (1,2). KIR2DL1 has been shown to be a potential clinical biomarker for diseases related to suppressed NK cell function (4). An increase in inhibitory receptors such as KIR2DL1/CD158a is observed in certain pathologies like endometriosis and multiple myeloma (4,5). Therapeutic inhibition of KIR2DL1 may be a potential treatment option for endometriosis patients (5). Additionally, blocking of KIR2DL1 combined with rituximab, and anti-CD20 monoclonal antibody, has shown increased NK cell cytotoxicity than just the antibody itself (5).
References
1. Debska-Zielkowska J, Moszkowska G, Zielinski M, et al. KIR Receptors as Key Regulators of NK Cells Activity in Health and Disease. Cells. 2021;10(7):1777. Published 2021 Jul 14. https://doi.org/10.3390/cells10071777
2. Goodson-Gregg FJ, Krepel SA, Anderson SK. Tuning of human NK cells by endogenous HLA-C expression. Immunogenetics. 2020;72(4):205-215. https://doi.org/10.1007/s00251-020-01161-x
3. Uniprotkb (P43626)
4. Konjevic G, Jurisic V, Jovic V, et al. Investigation of NK cell function and their modulation in different malignancies. Immunol Res. 2012;52(1-2):139-156. https://doi.org/10.1007/s12026-012-8285-7
5. Hoogstad-van Evert J, Paap R, Nap A, van der Molen R. The Promises of Natural Killer Cell Therapy in Endometriosis. Int J Mol Sci. 2022;23(10):5539. Published 2022 May 16. https://doi.org/10.3390/ijms23105539
Limitations
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are
guaranteed for 1 year from date of receipt.
Customers Who Viewed This Item Also Viewed...
Species: Hu
Applications: Block, CyTOF-reported, Flow
Species: Hu, Mu
Applications: ICC/IF, IHC, IHC-Fr, IHC-P, WB
Species: Hu
Applications: CyTOF-reported, Flow
Species: Hu
Applications: ELISA, Flow, ICC/IF, IHC, IHC-P, WB
Species: Hu
Applications: Block, CyTOF-ready, Flow
Species: Hu
Applications: CyTOF-ready, Flow, IP
Species: Hu
Applications: BA
Species: Hu
Applications: CyTOF-ready, Flow
Species: Hu
Applications: BA
Species: Hu, Mu
Applications: CyTOF-ready, Flow, ICC, KO, Simple Western, WB
Species: Hu, Mu
Applications: Flow-IC, Flow, ICC/IF, IHC, IHC-Fr, IHC-P, IP, WB
Species: Hu
Applications: CyTOF-ready, ELISA, Flow, ICC/IF, IHC, IHC-P, PA, WB
Species: Hu
Applications: BA
Species: Ca, Hu, Mu, Po
Applications: Flow, ICC/IF, IHC, IHC-Fr, IHC-P, KD
Species: Hu
Applications: Flow
Species: Hu
Applications: IHC, IHC-P, WB
Species: Hu
Applications: AgAct, CyTOF-reported, Flow
Species: Hu
Applications: CostimT, CyTOF-ready, Flow, Neut, WB
Species: Hu
Applications: CyTOF-ready, Flow
Species: Mu, Rt
Applications: Cell Depl, CyTOF-ready, Flow, ICC/IF, IHC, IHC-Fr, IHC-P, IP, InhibTFunc
Publications for KIR2DL1/CD158a Antibody (NBP2-11758JF549) (0)
There are no publications for KIR2DL1/CD158a Antibody (NBP2-11758JF549).
By submitting your publication information earn gift cards and discounts for future purchases.
Reviews for KIR2DL1/CD158a Antibody (NBP2-11758JF549) (0)
There are no reviews for KIR2DL1/CD158a Antibody (NBP2-11758JF549).
By submitting a review you will receive an Amazon e-Gift Card or Novus Product Discount.
- Review with no image -- $10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen
- Review with an image -- $25/€18/£15/$25 CAD/¥150 Yuan/¥2500 Yen
Product General Protocols
Find general support by application which include: protocols, troubleshooting, illustrated assays, videos and webinars.
Video Protocols
FAQs for KIR2DL1/CD158a Antibody (NBP2-11758JF549) (0)
Secondary Antibodies
| |
Isotype Controls
|
Additional KIR2DL1/CD158a Products
Research Areas for KIR2DL1/CD158a Antibody (NBP2-11758JF549)
Find related products by research area.
|
Blogs on KIR2DL1/CD158a